Ligand Pharmaceuticals Acquires APEIRON Biologics AG for $100M
Key Highlights Ligand Pharmaceuticals to acquire APEIRON Biologics AG for $100 million in cash. QARZIBA® (dinutuximab beta), an immunotherapy for high-risk…
Browsing Tag
Paul R. Edick
1 post